PharVision Advisers’s Telos TLS Stock Holding History

PharVision Advisers’s Portfolio TLS Stock Details TLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,871	Closed	-$58.1K	–	130
2026 Q1	$58.1K	Sell	13,871 -88,693	-86%	-$419K	0.59%	82
2025 Q4	$523K	Buy	+102,564	New	+$640K	0.26%	32

Other funds holding TLS

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

WCM

Weber Capital Management San Francisco, California $118M AUM

Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $83.9B AUM 60.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's TLS Position: Q2 2026 in Review

PharVision Advisers sold out of Telos (TLS) in Q2 2026, closing a stake of 13,871 shares — an estimated $58.1K sold.

PharVision Advisers first reported a position in TLS in Q4 2025 and held it in 2 quarters. The position peaked at $523K in Q4 2025. 160 funds tracked by Wall St. Rank hold TLS as of Q2 2026.

PharVision Advisers reported no remaining Telos position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 13,871 Telos shares in Q2 2026, an estimated $58.1K.
PharVision Advisers first reported a position in Telos in Q4 2025 and held it in 2 quarters.
PharVision Advisers's Telos position peaked at $523K in Q4 2025.
160 funds tracked by Wall St. Rank held Telos as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.